Genentech Sends Raptiva “Dear Doctor” Letter To Dermatologists, Nurses
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter addresses new warning in efalizumab labeling on immune-mediated hemolytic anemia. Two cases of hemolytic anemia were observed in clinical trials and two additional cases were observed in postmarketing adverse event monitoring.